New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to ...

Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...

Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy.

Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated ...

Image Caption: Proteomic alterations in post-NACT OCPM tissues. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the ...

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...